Table 2.

Total guideline-directed medical therapy intensifications per patient from pre-clinic visit to 30 days later.

	Treatment mean(sd) intensifications N = 145	Control mean(sd) intensifications N = 145	Estimate (95% CI) incidence rate ratio	p-value
Number of GDMT intensifications (initiation or dose increase EVBB, ACEI, ARB, ARNI, MRA, H/ISDN, or ivabradine)	0.61 (0.73)	0.36 (0.61)	1.7 (1.2, 2.4)	0.002
Number of all intensifications (including GDMT plus initiation or uptitration of loop diuretic or digoxin)	0.63 (0.73)	0.38 (0.62)	1.7 (1.2, 2.3)	0.002

ACE-I=angiotensin converting enzyme inhibitors; ARB= angiotensin receptor blockers; ARNI= angiotensin receptor neprilysin inhibitors; EVBB=evidence-based beta blocker; GDMT=guideline-directed medical therapy; H/ISDN=hydralazine/isosorbide dinitrate; MRA=mineralocorticoid receptor agonists

P values from Poisson model with fixed effect for clinic.